San Francisco startup Composition Therapeutics is likewise focusing on an oral, after-each day GLP-one drug identified as GSBR-1290—the drug surpassed Wall Street’s anticipations in June any time a mid-stage review showed regular weight loss of all over six% and it strategies to start out An additional mid-phase demo toward the end of the 12 mo… Read More